354200 엔젠바이오
기본 정보
- 섹터: KOSDAQ:일반서비스
- 시가총액: 197억원 (2026-06-30 기준)
- 첫 등장: — (마커 미등장)
- 태그: 매크로/바이오헬스 · 매크로/소비미디어 · NGS · 정밀진단 · 유전체분석 · 의약품유통 · 암진단
- 네이버 금융: 🔗
기업개요
- 동사는 2015년 설립된 NGS 기반 정밀진단 전문기업으로, 2020년 코스닥시장에 상장하였음.
- 2026년 엔젠파마와의 흡수합병을 완료하여 의약품 유통 사업을 영위하며, TOPLAB(미국), 엔젠헬스케어로 사업 포트폴리오를 다각화하고 있음.
- 정밀진단 사업부문에서는 NGS 기술을 활용한 암 정밀진단 패널과 유전체 분석 소프트웨어를 공급하고, 의약품 유통 사업부문에서는 의약품 도매 및 건강기능식품 유통 사업을 하고 있음.
출처: 네이버증권 종목분석 (WiseReport)
일자별 등장 (최신 위, 누적)
| 일자 | 전일 종가 | 종가 | 등락률 | 시간외 | vol | 색깔 | smart | 외 | 연 | 금투 | 투 | 개 | 그외 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | 2,040 | 1,998 | 🔵 -2.06% | — | ×0.2 | ⚫ 그외 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | -0.1 | +0.1 |
| 2026-08-13 | 2,045 | 2,040 | 🔵 -0.24% | — | ×0.4 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-08-12 | 2,275 | 2,045 | 🔵 -10.11% | — | ×0.5 | 🟢 외인 | +0.3억 | +0.3 | +0.0 | +0.0 | +0.0 | -0.2 | -0.1 |
| 2026-08-11 | 1,997 | 2,275 | 🔴 +13.92% | — | ×3.4 | 🔻 개인 | -0.8억 | -0.8 | +0.0 | +0.0 | +0.0 | +2.4 | -1.6 |
| 2026-08-10 | 1,828 | 1,997 | 🔴 +9.25% | — | ×0.2 | 🟢 외인 | +0.5억 | +0.5 | +0.0 | +0.0 | +0.0 | -0.5 | +0.0 |
| 2026-08-07 | 1,890 | 1,828 | 🔵 -3.28% | — | ×0.1 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.2 | +0.1 |
| 2026-08-06 | 1,738 | 1,890 | 🔴 +8.75% | — | ×0.1 | ⚫ 그외 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.1 |
| 2026-08-05 | 1,747 | 1,738 | 🔵 -0.52% | — | ×0.1 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.3 | +0.1 |
| 2026-08-04 | 1,660 | 1,747 | 🔴 +5.24% | — | ×0.1 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.2 | +0.1 |
| 2026-08-03 | 1,621 | 1,660 | 🔴 +2.41% | — | ×0.1 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-31 | 1,520 | 1,621 | 🔴 +6.64% | — | ×0.1 | 🟢 외인 | +0.0억 | +0.0 | +0.0 | -0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-30 | 1,545 | 1,520 | 🔵 -1.62% | — | ×0.1 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-29 | 1,745 | 1,545 | 🔵 -11.46% | — | ×0.1 | 🟢 외인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-28 | 2,205 | 1,745 | 🔵 -20.86% | — | ×0.4 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-27 | 2,585 | 2,205 | 🔵 -14.70% | — | ×1.2 | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.1 | -0.2 |
| 2026-07-24 | 1,990 | 2,585 | 🔴 +29.90% | — | ×4.1 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.3 | -0.1 |
| 2026-07-23 | 2,370 | 1,990 | 🔵 -16.03% | — | ×10.3 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | -0.3 | +0.0 | +0.5 | -0.1 |
| 2026-07-22 | 1,825 | 2,370 | 🔴 +29.86% | — | ×24.8 | 🔻 개인 | -0.9억 | -0.9 | +0.0 | +0.3 | +0.0 | +0.5 | +0.1 |
| 2026-07-21 | 1,669 | 1,825 | 🔴 +9.35% | — | ×1.9 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-20 | 1,668 | 1,669 | 🔴 +0.06% | — | ×0.3 | ⚫ 그외 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | -0.0 | +0.0 |
| 2026-07-16 | 1,710 | 1,668 | 🔵 -2.46% | — | ×0.7 | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | -0.0 |
| 2026-07-15 | 1,617 | 1,710 | 🔴 +5.75% | — | ×0.4 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-14 | 1,525 | 1,617 | 🔴 +6.03% | — | ×0.2 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-13 | 737 | 1,525 | 🔴 +106.92% | — | — | 🔻 개인 | -0.3억 | -0.3 | +0.0 | +0.0 | +0.0 | +0.3 | +0.1 |
| 2026-07-10 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-09 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-08 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-07 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-06 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-03 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-02 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-01 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-06-30 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-06-29 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-06-26 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-06-25 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-06-24 | 737 | 737 | ⚪ +0.00% | — | — | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-06-23 | 737 | 737 | ⚪ +0.00% | — | — | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | -0.2 | -0.0 | |
| 2026-06-22 | 792 | 737 | 🔵 -6.94% | — | ×0.9 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | -0.2 | -0.0 | |
| 2026-06-19 | 874 | 792 | 🔵 -9.38% | — | ×1.3 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.1 | +0.0 | |
| 2026-06-18 | 890 | 874 | 🔵 -1.80% | — | ×4.8 | 🟡 금투 | +0.2억 | +0.2 | +0.0 | +0.3 | -0.5 | +0.1 | |
| 2026-06-17 | 875 | 890 | 🔴 +1.71% | — | ×0.8 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | -0.1 | +0.0 |
일자별 사유 (최신 위)
2026-08-11
- 사유: —
- 섹터 컨텍스트: KOSDAQ:일반서비스 (smart -949억)
- 매크로 원인: 제약·바이오 개별 임상·허가 호재 잇따르며 급등 (통풍신약 3상 성공, 이상지질혈증제 허가 등) (높음)
2026-07-24
- 사유: 혈액암 진단 패널 공급 확대, 코오롱 임상실패 반사 진단주 급등
- 섹터 컨텍스트: KOSDAQ:일반서비스 (smart +235억)
- 매크로 원인: HLB 담도암 FDA 허가 기대에 진단·AI신약·비만약 등 바이오헬스 개별 호재 겹쳐 동반 강세 (보통)
2026-07-22
- 사유: 혈액암 진단 패널 공급 확대로 연일 급등
- 섹터 컨텍스트: KOSDAQ:일반서비스 (smart +237억)
- 매크로 원인: 삼성에피스-인투셀 ADC 기술이전·혈액암 진단 확대 등 개별 바이오 호재 겹침 (보통)